Important for atypical antipsychatic drugs: Pharmacokinetics, interaction potential and therapeutic drug monitoring;Wichtig bei atypischen antipsychotika: Pharmakokinetik, interaktionspotential und TDM

Pharmazie in Unserer Zeit

Volumn 31, Issue 6, 2002, Pages 546-557

  Härtter, Sebastian ^a   Hiemke, Christoph ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CARBAMAZEPINE; CLOZAPINE; CYCLOSPORIN; CYTOCHROME P450 3A4; DIBENZEPIN; DOPAMINE 2 RECEPTOR; ERYTHROMYCIN; FLUVOXAMINE; GLUCURONOSYLTRANSFERASE; KETOCONAZOLE; NEFAZODONE; NEUROLEPTIC AGENT; NORCLOZAPINE; OLANZAPINE; PAROXETINE; PERAZINE; PHENYTOIN; PROBENECID; PROCAINAMIDE; QUETIAPINE; RISPERIDONE; RITONAVIR; SULPIRIDE; THIORIDAZINE; UNINDEXED DRUG; VERAPAMIL; ZIPRASIDONE; ZOTEPINE;

AGRANULOCYTOSIS; CARDIOTOXICITY; CONTRACEPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG MONITORING; DRUG RECEPTOR BINDING; DRUG STRUCTURE; EXTRAPYRAMIDAL SYMPTOM; GENETIC POLYMORPHISM; HEREDITY; HUMAN; PATIENT COMPLIANCE; POSTMENOPAUSE; QT INTERVAL; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; SIDE EFFECT;

ANTIPSYCHOTIC AGENTS; BIOTRANSFORMATION; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; SCHIZOPHRENIA;

EID: 0036443341     PISSN: 00483664     EISSN: None     Source Type: Journal    
DOI: 10.1002/1615-1003(200211)31:6<546::AID-PAUZ546>3.0.CO;2-9     Document Type: Review

References (24)

1. Caccia, S.: Biotransformation of post-clozapine antipsychotics. Pharmacological implications. Clin Pharmacokinet 38 (2000), 393-414.
2. Ereshevsky, L.: Pharmacokinetics and drug interactions: Update for new antipsychotics. J Clin Psychiatry 57, Suppl. 11 (1996), 12-25.
3. Tonkin, A.L., Bochner, F.: Therapeutic drug monitoring and patient outcome. A review of the issues. Clin Pharmacokinet 27 (1994), 169-174.
4. Hiemke, C., Härtter, S., Weigmann, H.: Therapeutisches drug monitoring. In M. Gastpar, M. Banger (Hrsg.): Labormethoden in der Psychiatrischen Routine. Thieme, Stuttgart (2000), 106-133.
5. Mitchel, P.B.: Therapeutic drug monitoring of psychotropic medications. Br J Clin Pharmacol 49 (2000) 303-312.
6. Hiemke, C., Weigmann, H., Härtter, S., Mann, K.: Therapeutisches drug monitoring von psychopharmaka. Neurotransmitter 11 (2000), 52-55.
7. Prior, T.I., Chue, P.S., Tibbo, P., Baker, G.B.: Drug metabolism and atypical antipsychotics. Europ Neuropsychopharmacol 9 (1999), 301-309.
8. Byerly, M.J., de Vane, L.: Pharmacokinetics of clozapine and risperidone: A review of recent literature. J Clin Psychopharmacol 16 (1996), 177-187.
9. Schaber, G., Stevens, I., Gaertner, H.J., Dietz, K., Breyer-Pfaff, U.: Pharmacokinetics of clozapine and its metabolites in psychiatric patients: Plasma protein binding and renal clearance. Br J Clin Pharmacol 46 (1998), 453-459.
10. Gaertner, I., Gaertner, H.J., Vonthein, R., Dietz, K.: Therapeutic drug monitoring of clozapine in relapse prevention: A five-year prospective study. J Clin Psychopharmacol 21 (2001), 305-310.
11. Gründer, G., Vernaleken, I., Benkert, O.: Welche eigenschaften machen ein neuroleptikum atypisch? Nervenarzt 72 (2001), 833-843.
12. Brès, J., Bressolle, F.: Pharmacokinetics of sulpiride in humans after intravenous and intramuscular administrations. J Pharmaceutical Sciences 80 (1991), 1119-1124.
13. 2-Dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45 (1988), 71-76.
14. Müller, M.J.: Serum levels of sulpiride enantiomers after oral treatment with racemic sulpiride in psychiatric patients: A pilot study. Pharmacopsychiatry 34 (2001), 27-32.
15. Coukell, A.J., Spencer, C.M., Benfield, P.: Amisulpride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 6 (1996), 237-256.
16. Callaghan, J.T., Bergstom, R.F., Ptak, L.R., Beasley, C.M.: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 37 (1999), 177-193.
17. Rao, M.L., Hiemke, C., Grasmäder, K., Baumann, P.: Olanzapin: Pharmakologie, pharmakokinetik und therapeutisches drug monitoring. Fortschr Neurol Psychiat 69 (2001) 510-517.
18. Perry, P.J., Lund, B.C., Sanger, T., Beasley, C.: Olanzapine plasma concentrations and clinical response: Acute phase results of the north American olanzapine trial. J Clin Psychopharmacol 21 (2001), 14-20.
19. De Vane, L.C., Nemeroff, C.B.: Clinical pharmacokinetics of quetiapine. Clin Pharmacol 40 (2001) 509-522.
20. Small, J.G., Hirsch, S.R., Arvantis, L.A., Miller, B.G., Link, C.G.G. and the Seroquel Study Group. Quetiapine in patients schizophrenia. A high and a low-dose double-blind comparison with placebo. Arch Gen Psychiatry 54 (1997), 549-557.
21. Grant, S., Fitton, A.: Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 48 (1994), 253-273.
22. Spina, E., Avenoso, A., Facciolà, G., Salemi, M., Scordo, M.C., Ancione, M., Madia, A.G., Perucca, E.: Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology 153 (2001), 238-243.
23. Caeley, C.F., Cooper, C.K.: Ziprasidone: The fifth atypical antipsychotic. The Annals of Pharmacotherapy 36 (2002), 839-851.
24. Kondo, T., Otani, K., Ishida, M., Mihara, K., Osamu, T., Kaneko, S., Fukushuma, Y.: A study on the therapeutic spectrum of a fixed-dose of zotepine and its relationship with serum concentrations of the drug. Human Psychopharmacology 8 (1993), 133-139.